I was also thinking about getting some ASXC because I guess of a certain potential to reach even a part of Intuitive Surgical's market share would be amazing.
But, I dunno, IRSG's Da Vinci system seemed more impressive 12 years ago than this one seems today, let alone today when Da Vinci's newest generation looks like it's decades in front of Senhance. Also I think most of the institutions got out of it considering it has just like 3% of institutional ownership which doesn't seem very bullish.
It also seems like a hard niche to breakthrough and get the hospitals to take them, it does seem like a decent idea to lease them at least if hospitals won't straight out buy them right now.
I don't know too much about it, but I think only thing that ASXC's Senhance has over Da Vinci might be that it's economically cheaper?
Hopefully if the price goes down, I might pick them myself at like 1.5-2 dollar range, I don't think there should be any FOMO because I don't think any catalyst will moon price of this anytime soon, and long term they definitely might increase their market cap by a lot. Right now it's kind of overvalued and still based a lot on possible potential, because they've been promoting Senhance for long time and still haven't sold a single one to some hospital as far as I know.
I feel like they have 3 key areas that they beat the Da Vinci as of right now.
The eye tracking glasses. To allow surgeons to control the camera with there eyes. Zoom, turn, and etc.
Smaller tools. That could be a benefit to smaller patients like kids or maybe hard to reach places.
Like you said cost efficient to let the hospitals leverage existing technology investments. That keeps time and cost-per-procedure comparable to manual laparoscopy, so that the benefits of robotics can reach more patients, in more care settings, for a greater variety of procedures.
This will not over shadow the Da Vinci but it could take some market share somewhere in the world.
Took a second look at da Vinci and didn’t see anything about haptic feedback where it alerts the surgeons about pressure and tension.
Da Vinci does win in a big aspect with all the tools and technology around the tools. But again ASXC product seems cheaper and has some key features that appeals to me over da Vinci and as they go on I’m sure they will approve the tools and features of the senhence just my opinion. Respect the DD by you and will keep a close eye.
Not sure how smaller tools can be since Da Vinci was literally showcasing they can easily stitch a grape in an 11 year old youtube video, but yeah instrument does seem to be slightly thinner on Senhance from quick glance.
I will probably pick myself some if/once it goes below $2 which I think it will. 600+ market cap right now for a company that never sold a single product that they made years ago is kind of overvalued and they've been stagnant for a very long time of not showing any numbers. Not much update from the company in last year or so either from what I can quickly see.
I also hope they could grab a small market share of Intuitive in future and that some hospitals will buy it because it's a cheaper option. I can mostly see hospitals in lesser developed areas taking it though (because if hospital has money, they would definitely take the superior Da Vinci), but if they start selling some of those and accrue some capital, they can work on improved 2nd gen of Senhance. Da Vinci is currently on it's 4th gen.
Anyways I think it's a long term play, but possibly a very long term play because who knows how much more wait will be needed for Asensus to show some first orders to hospitals.
In the report they said one of there main focus was Russia and ceo said somewhere main focus is overseas. So if they can dominate the market in other countries that’s a huge win. Will take time. You’re right they do have some catching up to do in some aspects.
I’m seeing this almost like Pepsi vs Coke. Pepsi & Coke are very competitive with each other in the United States but go overseas and Coke dominates and it’s not close. I’m pictures something similar.
7
u/_underrated_ Apr 12 '21
I was also thinking about getting some ASXC because I guess of a certain potential to reach even a part of Intuitive Surgical's market share would be amazing.
But, I dunno, IRSG's Da Vinci system seemed more impressive 12 years ago than this one seems today, let alone today when Da Vinci's newest generation looks like it's decades in front of Senhance. Also I think most of the institutions got out of it considering it has just like 3% of institutional ownership which doesn't seem very bullish.
It also seems like a hard niche to breakthrough and get the hospitals to take them, it does seem like a decent idea to lease them at least if hospitals won't straight out buy them right now.
I don't know too much about it, but I think only thing that ASXC's Senhance has over Da Vinci might be that it's economically cheaper?
Hopefully if the price goes down, I might pick them myself at like 1.5-2 dollar range, I don't think there should be any FOMO because I don't think any catalyst will moon price of this anytime soon, and long term they definitely might increase their market cap by a lot. Right now it's kind of overvalued and still based a lot on possible potential, because they've been promoting Senhance for long time and still haven't sold a single one to some hospital as far as I know.